Immuno Vaccine Inc (IMMVF) 0.6700 $IMMVF Addiction

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 12:08 PM

Immuno Vaccine Inc (IMMVF) 0.6700 $IMMVF

Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 8.77 (+0.05), PFE: 33.99 (+0.05), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), ACUR: 0.80 (+0.03), JNJ: 102.30 (+0.47), INSY: 59.00 (+0.17), TRGT: 2.32 (unch), GILD: 109.30 (+0.56), AZN: 69.29 (-0.81), ABBV: 65.99 (+0.02), ARNA: 4.25 (unch)

Immunovaccine Announces Financial Results For Quarter Ended March 31, 2015
Marketwired - Tue May 12, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today released its financial and operational results for the quarter ended March 31, 2015.
IMV.TO: 0.81 (+0.03)

Immunovaccine Joins the OTCQX Marketplace in the United States
Marketwired - Mon Apr 27, 7:53AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, has been approved to trade on the OTCQX(R) Best Marketplace in the United States under the symbol "IMMVF". The Company will continue to trade on the Toronto Stock Exchange under the symbol "IMV".
IMV.TO: 0.81 (+0.03)

OTC Markets Group Welcomes Immunovaccine to OTCQX
PR Newswire - Mon Apr 27, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine development company, has qualified to trade on the OTCQX® Best Marketplace.
IMV.TO: 0.81 (+0.03)

Immunovaccine Provides Corporate Update and AGM Results
Marketwired - Thu Apr 16, 4:06PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX: IMV) is pleased to provide an update on recent clinical and preclinical research, corporate activities and the voting results of the annual and special meeting of shareholders of the Company.
IMV.TO: 0.81 (+0.03)

Immunovaccine to Present at American Association for Cancer Research (AACR) 2015 Annual Meeting
Marketwired - Wed Apr 15, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "Company"

(TSX: IMV), a clinical stage vaccine and immunotherapy company, announced today that a poster, highlighting the combination of DepoVax-based vaccines with an anti-PD-1 monoclonal antibody, will be presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR). The Annual Meeting will be held in Philadelphia, April 18-22, 2015. The data shows that DepoVax-based vaccines, when combined with anti-PD-1 therapy, lead to stronger anti-tumor activity than the anti-PD-1 therapy alone in multiple animal models.
IMV.TO: 0.81 (+0.03)

Immunovaccine to Present at World Vaccine Congress 2015
Marketwired - Tue Mar 31, 6:02AM CDT
Immunovaccine Inc. ("Immunovaccine"

(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will make a presentation and participate in a panel discussion at the World Vaccine Congress 2015. The conference will take place April 7-9, 2015 at the Walter E. Washington Convention Center in Washington D.C.
IMV.TO: 0.81 (+0.03)

Immunovaccine Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma
Marketwired - Tue Mar 24, 6:01AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"

(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that it has treated the first patient with diffuse large B cell lymphoma (DLBCL) in a Phase 2 clinical study of its lead cancer immunotherapy DPX-Survivac. The Company-sponsored trial is evaluating DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. DPX-Survivac is designed to activate killer T cells of the immune system against the survivin antigen found in a wide variety of solid tumors and blood cancers.
IMV.TO: 0.81 (+0.03)

GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 14.39 (+0.07)

Immunovaccine Announces 2014 Year-End Results
Marketwired - Fri Mar 20, 3:31PM CDT
Immunovaccine Inc. (TSX: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2014.
IMV.TO: 0.81 (+0.03)

Immunovaccine Announces Intent to Trade on OTCQX Marketplace in United States
Marketwired - Mon Mar 16, 6:02AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"

(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that it is seeking approval to have its common shares trade on the OTCQX(R) Best Marketplace. The trading of Immunovaccine's common shares on OTCQX is subject to review and approval by OTC Markets Group Inc. Immunovaccine's shares will continue to trade on the Toronto Stock Exchange under the symbol "IMV."
IMV.TO: 0.81 (+0.03)

Immunovaccine to Present at 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:02AM CST
Immunovaccine Inc. ("Immunovaccine"

(TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will present a corporate update at the 17th Annual BIO CEO & Investor Conference. The conference will take place February 9-10, 2015 at the Waldorf Astoria New York hotel.
IMV.TO: 0.81 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Right College Fit Crucial for Graduation Rates

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Abbe Lane's Estate Auction: Glamour Up for Grabs

Glamour from the Mid-Century Comes to the Auction Block In a world obsessed with the flavor of the month, a collection that truly turns heads by sailing in on a wave of genuine mid-century splendor isn't something you stumble upon every day. John Moran Auctioneers has the privilege to crack open the vault on the Estate of Abbe Lane, a name that once rolled off tongues...

J.H. Strain & Sons' Asset Sale Seals a New Era

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Navigate360 Data Breach Concerns: Legal Insights

No Safety in a Storm: Navigate360's Data Breach Fiasco When you think of data breaches, you often envision some shady hacker in a hoodie, but here we are with Navigate360 losing control of a massive chunk of sensitive data involving school safety tips. You'd hope companies with serious access to personal information are better at keeping secrets, right? Yet, here we are,...

Sinopec's Bold African Moves: Sustainability and WE17

A Bold African Initiative Alright, folks, let's get into the nitty-gritty of Sinopec's game plan in Africa. There's something to be said about a behemoth like Sinopec rolling out a sustainability report with real substance. We're looking at 33 projects across 16 countries, $5.7 billion in investments. Now, that's not just pocket change. Economic Muscle and Environmental...

A&S Construction Creates Winning Culture in Louisville

A&S Construction's Winning Formula: Culture Over Growth Look, in the dog-eat-dog world of construction, what really sets you apart isn't just how many roofs you stack up or the number of renovations you churn through. It's how you treat your people. And A&S Construction of Louisville gets that—ranking No. 6 in its category on the 2026 Best Places to Work list, all while...

SELCO and Numerica Unite: A Merger That's All Heart

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...

Ameritas Hires Actuarial Veteran as VP in Strategic Move

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Fed Holds Steady, But CD Rates Climb: Savers' Edge

The Fed Sits Tight, But CD Rates Surge Isn't it a kicker when the Fed holds rates steady, yet the CD market is buzzing like a crowded trading floor on a bull run? We've seen the Federal Reserve hold its ground without budging interest rates, keeping everyone guessing while inflation's still a shadow in the corner. But the star of the show here isn't the Fed's poker...